文献速递中药与中成药合理使用中医儿科

小儿柴翘清热颗粒全链条质量控制:从过程风险管理到智能产品检测

Data-driven full-chain quality control for Xiaoer Chiqiao Qingre granules: from process risk management to intelligent product testing.
PubMed 文献 · Chin Med · 2026-05-12

本研究以小儿柴翘清热颗粒为对象,在质量源于设计框架下结合HPLC多成分定量、色谱与物理指纹图谱监测提取至药液收集全过程,并以Plackett-Burman设计筛选关键工艺参数、Box-Behnken建立醇沉设计空间,同时开发机器视觉快速评价颗粒外观。

要点

  • 醇沉是11个监测成分损失最大的环节,平均降低23.6%。
  • 浓缩阶段maackiain-7-O-glucoside下降38.1%,醇沉后黄酮等浓缩因子1.50-1.56。
  • 机器视觉系统识别与异常批次剔除准确率均达100%。

核心结论

  • 提出「过程分析-参数优化-智能监测」全链条策略,为小儿柴翘清热颗粒质量控制提供稳健框架,推动中药制造由经验驱动转向数据驱动。

研究设计与样本

  • 在质量源于设计框架下,采用HPLC多成分定量、色谱指纹图谱与物理指纹图谱监测提取、浓缩、醇沉与药液收集全过程。
  • 以Plackett-Burman设计筛选关键工艺参数,用Box-Behnken响应面法建立醇沉工艺设计空间,并开发机器视觉系统评价颗粒外观。

主要发现

  • 醇沉导致11个监测成分平均损失23.6%,为各环节中最大。
  • 浓缩阶段maackiain-7-O-glucoside下降38.1%。
  • 醇沉后黄酮、苯乙醇苷与萜类的浓缩因子分别为1.56、1.53与1.50,提示保留率与化合物极性呈负相关。
  • 工艺过程中成分再分布显著降低黏度RSD,提示体系均一性改善且成分-性质相关性发生反转。
  • 以代表性成分为CQA建立的稳健回归模型Adj R2均大于0.85,所定义设计空间在最大化CQA保留的同时降低批间变异。

关键数值与推荐

  • 以萜类、黄酮与苯乙醇苷的保留率定义为关键质量属性(CQA)。
  • 醇沉后黄酮、苯乙醇苷与萜类的浓缩因子分别为1.56、1.53与1.50。
  • 稳健回归模型Adj R2大于0.85用于定义设计空间。
  • 机器视觉系统识别与异常批次剔除准确率均为100%。

临床怎么用

  • 可将醇沉作为重点监控环节,关注极性较强成分的保留率变化。
  • 可参考所建立的设计空间与稳健回归模型优化醇沉参数,以兼顾CQA保留与批间一致性。
  • 机器视觉可用于颗粒外观的快速无损评价与异常批次剔除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Xiaoer Chiqiao Qingre granules (XECQ) is a widely used traditional Chinese medicine for the treatment of pediatric wind-heat colds. However, its multi-step manufacturing process results in substantial inter-batch variability, posing a challenge for consistent quality control. Guided by the Quality by Design (QbD) concept, this study developed an integrated framework that combines process analysis, parameter optimization, and intelligent monitoring to improve batch-to-batch consistency and ensure medication safety. METHODS: Within the QbD framework, HPLC-based multi-component quantification, chromatographic fingerprinting, and physical fingerprinting were employed to monitor quality across the entire manufacturing process, including extraction, concentration, alcohol precipitation, and decoction collection. Eleven active constituents were quantitatively characterized, and their relationships with key physicochemical properties were analyzed. The retention rates of terpenoids, flavonoids, and phenylethanoid glycosides were defined as critical quality attributes (CQAs). Critical process parameters were screened using a Plackett-Burman design, and the design space for the alcohol precipitation process was established through Box-Behnken response surface methodology. In addition, a machine vision system was developed for rapid, non-destructive evaluation of particle appearance. RESULTS: Alcohol precipitation resulted in the greatest loss among the 11 monitored components, with an average reduction of 23.6%, whereas maackiain-7-O-glucoside exhibited a marked decrease of 38.1% during the concentration stage. After alcohol precipitation, the concentration factors of flavonoids, phenylethanoid glycosides, and terpenoids were 1.56, 1.53, and 1.50, respectively, suggesting a negative correlation between retention rate and compound polarity. Component redistribution during processing significantly reduced the relative standard deviation (RSD) of viscosity, indicating improved system homogeneity and a reversal of component-property correlations. Using these representative components as CQAs, robust regression models (Adj R2 > 0.85) were established to define a design space that maximized CQA retention while minimizing batch-to-batch variability. Furthermore, the machine vision system achieved 100% accuracy in both identification and abnormal batch rejection. CONCLUSION: This study proposes a holistic "Process Analysis-Parameter Optimization-Intelligent Monitoring" strategy, providing a robust framework for enhancing the quality control of XECQ and facilitating the transition of TCM manufacturing from empirically driven practices to data-driven processes.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Wang N, Chang Y, Cheng Y, et al. Data-driven full-chain quality control for Xiaoer Chiqiao Qingre granules: from process risk management to intelligent product testing. Chin Med. 2026. PMID: 42116200. doi:10.1186/s13020-026-01414-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。